AGA临床实践更新:难治性乳糜泻的管理专家评述
美国胃肠病学会(AGA)发布难治性乳糜泻管理专家评述,提出10条最佳实践建议。内容涵盖确诊复核、排除麸质摄入、系统评估其他病因、难治性乳糜泻分型鉴别、影像学排查淋巴瘤、营养评估与支持、糖皮质激素一线治疗及多学科随访,因未做系统评价故未给出证据质量或推荐强度分级。
要点
- 持续或复发症状者应先复核原诊断,并排除持续摄入麸质。
- 排除麸质后需系统排查功能性肠病、显微镜结肠炎、胰腺功能不全等。
- 1型与2型难治性乳糜泻靠流式细胞术、免疫组化及T细胞受体重排区分。
核心结论
- 本专家评述总结了难治性乳糜泻的诊断与管理,并提出10条最佳实践建议。
- 因未进行系统评价,这些建议不附带正式的证据质量或推荐强度分级。
研究设计与样本
- 由AGA研究所临床实践更新委员会(CPUC)和AGA理事会委托并批准,经内部同行评议和《Gastroenterology》标准外部同行评议。
- 建议来自已发表文献综述与专家意见,未进行系统评价。
主要发现
- 对疑似乳糜泻且持续或复发症状者,应通过复核既往血清学、内镜和组织学检查确认初始诊断。
- 确诊乳糜泻但持续或复发症状(非反应性乳糜泻)者,应通过血清学、营养师复核及粪便或尿液免疫原性肽检测排除持续摄入麸质。
- 应行食管胃十二指肠镜及小肠活检寻找绒毛萎缩;若绒毛萎缩持续或初始诊断未确认,需考虑普通变异型免疫缺陷、自身免疫性肠病、热带口炎性腹泻和药物性肠病等其他原因。
- 排除麸质摄入后,应系统评估功能性肠病、显微镜结肠炎、胰腺功能不全、炎症性肠病、乳糖或果糖不耐受及小肠细菌过度生长等其他病因。
- 用流式细胞术、免疫组化和T细胞受体重排研究区分难治性乳糜泻亚型并排除肠病相关T细胞淋巴瘤;1型为上皮内淋巴细胞群正常,2型为存在异常克隆性上皮内淋巴细胞群,需专家血液病理学家会诊解读。
关键数值与推荐
- 最佳实践建议1:对疑似乳糜泻且持续或复发症状或体征者,应通过复核既往诊断检测(包括血清学、内镜和组织学发现)确认初始诊断。
- 最佳实践建议2:对确诊乳糜泻且持续或复发症状或体征者,应通过血清学检测、营养师复核及粪便或尿液免疫原性肽检测排除持续摄入麸质;应行食管胃十二指肠镜及小肠活检寻找绒毛萎缩,若绒毛萎缩持续或初始诊断未确认,考虑其他绒毛萎缩原因。
- 最佳实践建议3:对非反应性乳糜泻,排除麸质摄入后,应系统评估其他潜在病因,包括功能性肠病、显微镜结肠炎、胰腺功能不全、炎症性肠病、乳糖或果糖不耐受及小肠细菌过度生长。
- 最佳实践建议4:用流式细胞术、免疫组化和T细胞受体重排研究区分难治性乳糜泻亚型并排除肠病相关T细胞淋巴瘤;1型为上皮内淋巴细胞群正常,2型为存在异常克隆性上皮内淋巴细胞群,需专家血液病理学家会诊解读。
- 最佳实践建议5:2型难治性乳糜泻初始诊断时,应行胶囊内镜及计算机断层扫描或磁共振小肠造影的小肠影像学检查,以排除肠病相关T细胞淋巴瘤和溃疡性空回肠炎。
临床怎么用
- 最佳实践建议6:对确诊难治性乳糜泻者完成详细营养评估,检查微量营养素和宏量营养素缺乏,并检查白蛋白作为独立预后因素。
- 最佳实践建议7:用口服补充剂和/或肠内支持纠正宏量和微量营养素缺乏;对因吸收不良导致严重营养不良者考虑肠外营养。
- 最佳实践建议8:糖皮质激素(最常用开放胶囊布地奈德,若不可用则用泼尼松)是首选药物,应作为1型或2型难治性乳糜泻的一线治疗。
- 最佳实践建议9:难治性乳糜泻患者需由包括胃肠病学家和营养师在内的多学科团队定期随访,评估临床和组织学治疗反应;确定具有乳糜泻专长的本地专家协助管理。
- 最佳实践建议10:对类固醇无反应的难治性乳糜泻患者,转诊至具有管理专长的中心或评估参加临床试验可能获益。
局限性
- 原文未进行系统评价,因此这些最佳实践建议不附带正式的证据质量或推荐强度分级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DESCRIPTION: The purpose of this expert review is to summarize the diagnosis and management of refractory celiac disease. It will review evaluation of patients with celiac disease who have persistent or recurrent symptoms, differential diagnosis, nutritional support, potential therapeutic options, and surveillance for complications of this condition. METHODS: This expert review was commissioned and approved by the American Gastroenterological Association (AGA) Institute Clinical Practice Updates Committee (CPUC) and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership and underwent internal peer review by the CPUC and external peer review through standard procedures of Gastroenterology. These Best Practice Advice (BPA) statements were drawn from a review of the published literature and from expert opinion. Since systematic reviews were not performed, these BPA statements do not carry formal ratings of the quality of evidence or strength of the presented considerations. Best Practice Advice Statements BEST PRACTICE ADVICE 1: In patients believed to have celiac disease who have persistent or recurrent symptoms or signs, the initial diagnosis of celiac disease should be confirmed by review of prior diagnostic testing, including serologies, endoscopies, and histologic findings. BEST PRACTICE ADVICE 2: In patients with confirmed celiac disease with persistent or recurrent symptoms or signs (nonresponsive celiac disease), ongoing gluten ingestion should be excluded as a cause of these symptoms with serologic testing, dietitian review, and detection of immunogenic peptides in stool or urine. Esophagogastroduodenoscopy with small bowel biopsies should be performed to look for villous atrophy. If villous atrophy persists or the initial diagnosis of celiac disease was not confirmed, consider other causes of villous atrophy, including common variable immunodeficiency, autoimmune enteropathy, tropical sprue, and medication-induced enteropathy. BEST PRACTICE ADVICE 3: For patients with nonresponsive celiac disease, after exclusion of gluten ingestion, perform a systematic evaluation for other potential causes of symptoms, including functional bowel disorders, microscopic colitis, pancreatic insufficiency, inflammatory bowel disease, lactose or fructose intolerance, and small intestinal bacterial overgrowth. BEST PRACTICE ADVICE 4: Use flow cytometry, immunohistochemistry, and T-cell receptor rearrangement studies to distinguish between subtypes of refractory celiac disease and to exclude enteropathy-associated T-cell lymphoma. Type 1 refractory celiac disease is characterized by a normal intraepithelial lymphocyte population and type 2 is defined by the presence of an aberrant, clonal intraepithelial lymphocyte population. Consultation with an expert hematopathologist is necessary to interpret these studies. BEST PRACTICE ADVICE 5: Perform small bowel imaging with capsule endoscopy and computed tomography or magnetic resonance enterography to exclude enteropathy-associated T-cell lymphoma and ulcerative jejunoileitis at initial diagnosis of type 2 refractory celiac disease. BEST PRACTICE ADVICE 6: Complete a detailed nutritional assessment with investigation of micronutrient and macronutrient deficiencies in patients diagnosed with refractory celiac disease. Check albumin as an independent prognostic factor. BEST PRACTICE ADVICE 7: Correct deficiencies in macro- and micronutrients using oral supplements and/or enteral support. Consider parenteral nutrition for patients with severe malnutrition due to malabsorption. BEST PRACTICE ADVICE 8: Corticosteroids, most commonly open-capsule budesonide or, if unavailable, prednisone, are the medication of choice and should be used as first-line therapy in either type 1 or type 2 refractory celiac disease. BEST PRACTICE ADVICE 9: Patients with refractory celiac disease require regular follow-up by a multidisciplinary team, including gastroenterologists and dietitians, to assess clinical and histologic response to therapy. Identify local experts with expertise in celiac disease to assist with management. BEST PRACTICE ADVICE 10: Patients with refractory celiac disease without response to steroids may benefit from referral to a center with expertise for management or evaluation for inclusion in clinical trials.
引用
- Green PHR, Paski S, Ko CW, et al. AGA Clinical Practice Update on Management of Refractory Celiac Disease: Expert Review. Gastroenterology. 2022. PMID: 36137844. doi:10.1053/j.gastro.2022.07.086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。